

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8321071

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ZHAOKUI WAN	11/22/2023
MICHAEL LAWRENCE VAZQUEZ	11/21/2023
XIAODONG LI	11/22/2023
JINGYU WU	11/14/2023
LIN SU	11/15/2023
GURMIT GREWAL	11/17/2023
RECEIVING PARTY DATA	
Name:	LYNK PHARMACEUTICALS CO. LTD.
Street Address:	FUCHENG ROAD ROOM 5-402, NO. 291
Internal Address:	HANGZHOU ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE
City:	HANGZHOU
State/Country:	CHINA
PROPERTY NUMBERS Total: 4	
Property Type	Number
PCT Number:	CN2021138744
PCT Number:	CN2022106876
PCT Number:	CN2022139649
Application Number:	18372417
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6175298369
Email:	philip.zhang@mzwiplaw.com
Correspondent Name:	MILSTEIN ZHANG & WU LLC
Address Line 1:	2000 COMMONWEALTH AVENUE SUITE 400
Address Line 4:	NEWTON, MASSACHUSETTS 02466
ATTORNEY DOCKET NUMBER:	LNK-012
NAME OF SUBMITTER:	YIN PHILIP ZHANG

SIGNATURE:	/Yin P. Zhang 44372/
DATE SIGNED:	12/09/2023
Total Attachments: 12 source=LNK-012_Assignment and Declaration_Wan#page1.tif source=LNK-012_Assignment and Declaration_Wan#page2.tif source=LNK-012_Assignment and Declaration_Li#page1.tif source=LNK-012_Assignment and Declaration_Li#page2.tif source=LNK-012_Assignment and Declaration_Wu#page1.tif source=LNK-012_Assignment and Declaration_Wu#page2.tif source=LNK-012_Assignment and Declaration_Su#page1.tif source=LNK-012_Assignment and Declaration_Su#page2.tif source=LNK-012_Assignment and Declaration_Vazquez#page1.tif source=LNK-012_Assignment and Declaration_Vazquez#page2.tif source=LNK-012_Assignment and Declaration_Grewal#page1.tif source=LNK-012_Assignment and Declaration_Grewal#page2.tif	

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: Zhaokui Wan

ASSIGNEE: Lynk Pharmaceuticals Co. LTD.

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No. PCT/CN2021/138744, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2021; Application Serial No. PCT/CN2022/106876, filed with the Chinese Intellectual Property Office on JULY 20, 2022; and Application Serial No. PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, **Lynk Pharmaceuticals Co. LTD.**, having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.


Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent

applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: 
Legal Name of Inventor: Zhaokui Wan
Nationality: USA

Date: 11/22/2003

[END OF DOCUMENT]

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: Xiaodong Li

ASSIGNEE: Lynk Pharmaceuticals Co. LTD.

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No. PCT/CN2021/138744, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2021; Application Serial No. PCT/CN2022/106876, filed with the Chinese Intellectual Property Office on JULY 20, 2022; and Application Serial No. PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, **Lynk Pharmaceuticals Co. LTD.**, having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.

Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent

applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: _____

Xiaodong Li

Date: _____

Nov - 22nd, 2023

Legal Name of Inventor: **Xiaodong Li**

Nationality: **China**

[END OF DOCUMENT]

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: **Jingyu Wu**

ASSIGNEE: **Lynk Pharmaceuticals Co. LTD.**

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No.

PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, **Lynk Pharmaceuticals Co. LTD.**, having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.

Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary

protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: Jingyu Wu
Legal Name of Inventor: Jingyu Wu
Nationality: China

Date: 2023.11.14

[END OF DOCUMENT]

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: Lin Su

ASSIGNEE: Lynk Pharmaceuticals Co. LTD.

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No. PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, Lynk Pharmaceuticals Co. LTD., having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.

Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-

part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: _____



Date: _____

2023. 11. 15

Legal Name of Inventor: **Lin Su**

Nationality: **China**

[END OF DOCUMNT]

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: **Michael Lawrence Vazquez**

ASSIGNEE: **Lynk Pharmaceuticals Co. LTD.**

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No.

PCT/CN2021/138744, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2021; Application Serial No. PCT/CN2022/106876, filed with the Chinese Intellectual Property Office on JULY 20, 2022; and Application Serial No. PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, **Lynk Pharmaceuticals Co. LTD.**, having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.

Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent


applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature:


Legal Name of Inventor: Michael Lawrence Vazquez

Date:

11-21-2023

Nationality: USA

[END OF DOCUMENT]

ASSIGNMENT AND DECLARATION

Title of Invention: TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

ASSIGNOR: **Gurmit Grewal**

ASSIGNEE: **Lynk Pharmaceuticals Co. LTD.**

As the below named inventor, I (herein referred to as the "ASSIGNOR") hereby declare that:

This Assignment and Declaration is directed to PCT Application Serial No. PCT/CN2022/139649, filed with the Chinese Intellectual Property Office on DECEMBER 16, 2022.

Whereas, ASSIGNOR has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application(s) (herein referred to as the "APPLICATION");

The INVENTION was made or authorized to be made by ASSIGNOR, and ASSIGNOR has reviewed and understand the contents of the APPLICATION, including the claims;

ASSIGNOR believes that s/he is an original inventor or an original joint inventor of a claimed invention in the APPLICATION;

ASSIGNOR is aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56; and

Whereas, **Lynk Pharmaceuticals Co. LTD.**, having an address at Hangzhou Economic and Technological Development Zone, Fucheng Road Room 5-402, No. 291, Zhejiang Province, China (herein referred to as "ASSIGNEE"), desires to attain or has attained, and ASSIGNOR desires to grant or has granted to ASSIGNEE, the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto; and

At the time the INVENTION was made, ASSIGNOR was an employee of ASSIGNEE. The conditions under which the INVENTION was made are such that as defined in the contract as an employee of ASSIGNEE, ASSIGNOR automatically entitles and assigns ASSIGNEE to the entire worldwide right, title, and interest in and to the INVENTION and improvements thereof, including the worldwide right to claim priority to a priority application for the INVENTION, both domestic and foreign, and in and to any and all patent applications and patents directed thereto.

Now, therefore, for good and valuable consideration, the receipt of which from the ASSIGNEE and sufficiency thereof being hereby acknowledged by ASSIGNOR, ASSIGNOR, for the avoidance of doubt, hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, including the right to claim priority to a priority application for the INVENTION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisionals, continuations, continuations-in-

part, reissues, reexaminations, renewals, counterparts, substitutes, extensions, and supplementary protection certificates thereof, and all foreign equivalents thereof, and all rights of priority resulting from the filing of such applications and granting of such patents, and further including any right to sue for all infringement. In addition, ASSIGNOR hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on the improvements or resulting therefrom to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment and Declaration not been made; and ASSIGNOR agrees to execute any and all documents, oaths and instruments and perform all lawful acts reasonably related to recording this Assignment and Declaration or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

ASSIGNOR also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment and Declaration any further identification of the APPLICATION (including, but not limited to, patent Application Numbers and filing dates).

ASSIGNOR covenants that ASSIGNOR has the full right and obligation to convey the interest assigned herein, and ASSIGNOR has not executed and will not execute any agreement in conflict with this Assignment and Declaration.

ASSIGNOR hereby acknowledges that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: _____



Legal Name of Inventor: **Gurmit Grewal**

Nationality: **USA**

Date: _____

Nov. 17, 2023

[END OF DOCUMENT]